Join
Live feed
·
PRReleasevia Quantisnow
TG Therapeutics Inc. logo

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

ByQuantisnow·Wall Street's wire, on your screen.
TGTX· TG Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TGTX (TG Therapeutics Inc.) and more on Quantisnow.